{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:39:02Z","timestamp":1791362342533,"version":"4.3.1"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K1498301"],"award-info":[{"award-number":["21K1498301"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H02503"],"award-info":[{"award-number":["22H02503"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Immune checkpoint inhibitors (ICIs) have been developed for canine tumour treatment, and pilot clinical studies have demonstrated their antitumour efficacy in dogs with oral malignant melanoma (OMM). Although ICIs have been approved for various human malignancies, their clinical benefits in other tumour types remain to be elucidated in dogs. Here, we conducted a clinical study of c4G12, a canine chimeric anti-PD-L1 antibody, to assess its safety and efficacy in dogs with various advanced malignant tumours (\n                    <jats:italic>n<\/jats:italic>\n                    = 12) at the Veterinary Teaching Hospital of Hokkaido University from 2018 to 2023. Dogs with digit or foot pad malignant melanoma (\n                    <jats:italic>n<\/jats:italic>\n                    = 4), osteosarcoma (\n                    <jats:italic>n<\/jats:italic>\n                    = 2), hemangiosarcoma (\n                    <jats:italic>n<\/jats:italic>\n                    = 1), transitional cell carcinoma (\n                    <jats:italic>n<\/jats:italic>\n                    = 1), nasal adenocarcinoma (\n                    <jats:italic>n<\/jats:italic>\n                    = 1), B-cell lymphoma (\n                    <jats:italic>n<\/jats:italic>\n                    = 1), or undifferentiated sarcoma (\n                    <jats:italic>n<\/jats:italic>\n                    = 2) were treated with 2 or 5 mg\/kg c4G12 every 2 weeks. Treatment-related adverse events of any grade were observed in eight dogs (66.7%), including elevated aspartate aminotransferase (grade 3) in one dog (8.3%) and thrombocytopenia (grade 4) in another dog (8.3%). Among dogs with target disease at baseline (\n                    <jats:italic>n<\/jats:italic>\n                    = 8), as defined by the response evaluation criteria for solid tumours in dogs (cRECIST), one dog with nasal adenocarcinoma and another with osteosarcoma experienced a partial response (PR), with an objective response rate of 25.0% (2 PR out of 8 dogs; 95% confidence interval: 3.2\u201365.1%). These results suggest that c4G12 is safe and tolerable and shows antitumor effects in dogs with malignant tumours other than OMM. Further clinical studies are warranted to identify the tumour types that are most likely to benefit from c4G12 treatment.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0291727","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T13:24:52Z","timestamp":1696425892000},"page":"e0291727","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours"],"prefix":"10.1371","volume":"18","author":[{"given":"Naoya","family":"Maekawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3230-7109","authenticated-orcid":true,"given":"Satoru","family":"Konnai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Owaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":true,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-1494","authenticated-orcid":true,"given":"Yasuhiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Okagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"pone.0291727.ref001","first-page":"2057","article-title":"Variation in age at death of dogs of different sexes and breeds","volume":"43","author":"RT Bronson","year":"1982","journal-title":"Am J Vet Res"},{"key":"pone.0291727.ref002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1748-5827.2010.00974.x","article-title":"Methods and mortality results of a health survey of purebred dogs in the UK","volume":"51","author":"VJ Adams","year":"2010","journal-title":"J Small Anim Pract"},{"key":"pone.0291727.ref003","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.prevetmed.2015.03.018","article-title":"A current life table and causes of death for insured dogs in Japan","volume":"120","author":"M Inoue","year":"2015","journal-title":"Prev Vet Med"},{"key":"pone.0291727.ref004","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1748-5827.2002.tb00066.x","article-title":"Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs","volume":"43","author":"JM Dobson","year":"2002","journal-title":"J Small Anim Pract"},{"key":"pone.0291727.ref005","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/vr.b4808","article-title":"Data from the Danish veterinary cancer registry on the occurrence and distribution of neoplasms in dogs in Denmark","volume":"166","author":"LB Br\u00f8nden","year":"2010","journal-title":"Vet Rec"},{"key":"pone.0291727.ref006","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.7150\/thno.55760","article-title":"Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?","volume":"11","author":"I Beltr\u00e1n Hern\u00e1ndez","year":"2021","journal-title":"Theranostics"},{"key":"pone.0291727.ref007","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"SL Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0291727.ref008","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"JR Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0291727.ref009","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Y Iwai","year":"2017","journal-title":"J Biomed Sci"},{"key":"pone.0291727.ref010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"S Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"pone.0291727.ref011","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"H Dong","year":"2002","journal-title":"Nat Med"},{"key":"pone.0291727.ref012","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"L Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"pone.0291727.ref013","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"M Sznol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"pone.0291727.ref014","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41379-019-0210-3","article-title":"Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases","volume":"32","author":"DP O\u2019Malley","year":"2019","journal-title":"Mod Pathol"},{"key":"pone.0291727.ref015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"JJ Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"pone.0291727.ref016","doi-asserted-by":"crossref","first-page":"eabo3605","DOI":"10.1126\/scitranslmed.abo3605","article-title":"Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment","volume":"14","author":"N Kirchhammer","year":"2022","journal-title":"Sci Transl Med"},{"key":"pone.0291727.ref017","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/13543784.2022.2009456","article-title":"Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects","volume":"31","author":"A Rizzo","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"pone.0291727.ref018","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"M Santoni","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"pone.0291727.ref019","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"N Maekawa","year":"2017","journal-title":"Sci Rep"},{"key":"pone.0291727.ref020","doi-asserted-by":"crossref","first-page":"18311","DOI":"10.1038\/s41598-020-75533-4","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"M Igase","year":"2020","journal-title":"Sci Rep"},{"key":"pone.0291727.ref021","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-021-00147-6","article-title":"PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma","volume":"5","author":"N Maekawa","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"pone.0291727.ref022","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/vco.12829","article-title":"Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: A follow-up case report","volume":"20","author":"M Igase","year":"2022","journal-title":"Vet Comp Oncol"},{"key":"pone.0291727.ref023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/j.ctsap.2007.03.004","article-title":"Canine oral melanoma","volume":"22","author":"PJ Bergman","year":"2007","journal-title":"Clin Tech Small Anim Pract"},{"key":"pone.0291727.ref024","doi-asserted-by":"crossref","first-page":"e98415","DOI":"10.1371\/journal.pone.0098415","article-title":"Expression of PD-L1 on canine tumor cells and enhancement of IFN-\u03b3 production from tumor-infiltrating cells by PD-L1 blockade","volume":"9","author":"N Maekawa","year":"2014","journal-title":"PLoS One"},{"key":"pone.0291727.ref025","first-page":"195","article-title":"Programmed Cell Death Ligand 1 Expression in Canine Cancer","volume":"30","author":"K Shosu","year":"2016","journal-title":"In Vivo"},{"key":"pone.0291727.ref026","doi-asserted-by":"crossref","first-page":"e0157176","DOI":"10.1371\/journal.pone.0157176","article-title":"Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma","volume":"11","author":"N Maekawa","year":"2016","journal-title":"PLoS One"},{"key":"pone.0291727.ref027","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/vco.12197","article-title":"Immune regulation of canine tumour and macrophage PD-L1 expression","volume":"15","author":"G Hartley","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"pone.0291727.ref028","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/vco.12297","article-title":"Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors","volume":"15","author":"SR Kumar","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"pone.0291727.ref029","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41598-022-06203-w","article-title":"Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages","volume":"12","author":"KCM Gulay","year":"2022","journal-title":"Sci Rep"},{"key":"pone.0291727.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14246188","article-title":"Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma","volume":"14","author":"L Minoli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"pone.0291727.ref031","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/vco.283","article-title":"Veterinary cooperative oncology group\u2014common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","author":"Veterinary Cooperative Oncology Group (VCOG)","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"pone.0291727.ref032","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"SM Nguyen","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"pone.0291727.ref033","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.2460\/javma.242.11.1534","article-title":"Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma","volume":"242","author":"DR Schrempp","year":"2013","journal-title":"J Am Vet Med Assoc"},{"key":"pone.0291727.ref034","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/vco.12222","article-title":"Retrospective comparison of three doses of metronomic chlorambucil for tolerability and efficacy in dogs with spontaneous cancer","volume":"15","author":"MR Custead","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"pone.0291727.ref035","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/j.wneu.2018.05.027","article-title":"Canine (Pet Dog) Tumor Microsurgery and Intratumoral Concentration and Safety of Metronomic Chlorambucil for Spontaneous Glioma: A Phase I Clinical Trial","volume":"116","author":"RT Bentley","year":"2018","journal-title":"World Neurosurg"},{"key":"pone.0291727.ref036","doi-asserted-by":"crossref","first-page":"530478","DOI":"10.3389\/fonc.2020.530478","article-title":"Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review","volume":"10","author":"X Liu","year":"2020","journal-title":"Front Oncol"},{"key":"pone.0291727.ref037","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"MH Kroll","year":"2022","journal-title":"Blood"},{"key":"pone.0291727.ref038","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"F Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"pone.0291727.ref039","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/OP.21.00776","article-title":"Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy","volume":"18","author":"BJ Schneider","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"pone.0291727.ref040","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/jvim.12603","article-title":"The immunotherapy of canine osteosarcoma: a historical and systematic review","volume":"29","author":"KL Wycislo","year":"2015","journal-title":"J Vet Intern Med"},{"key":"pone.0291727.ref041","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jvim.15852","article-title":"Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma","volume":"34","author":"BK Flesner","year":"2020","journal-title":"J Vet Intern Med"},{"key":"pone.0291727.ref042","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1078-0432.CCR-21-2105","article-title":"Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma","volume":"28","author":"DP Regan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"pone.0291727.ref043","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-18-0751","article-title":"CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer","volume":"7","author":"S Maeda","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"pone.0291727.ref044","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","article-title":"Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment","volume":"25","author":"H Sato","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"pone.0291727.ref045","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"SP Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"pone.0291727.ref046","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1","volume":"48","author":"C Sun","year":"2018","journal-title":"Checkpoint. Immunity"},{"key":"pone.0291727.ref047","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"M Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"pone.0291727.ref048","article-title":"Regulation of programmed death ligand 1 expression by interferon-\u03b3 and tumour necrosis factor-\u03b1 in canine tumour cell lines","author":"R Owaki","year":"2023","journal-title":"Vet Comp Oncol"},{"key":"pone.0291727.ref049","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fvets.2020.00330","article-title":"Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers","volume":"7","author":"H Takeuchi","year":"2020","journal-title":"Front Vet Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T13:25:15Z","timestamp":1696425915000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291727"}},"subtitle":[],"editor":[{"given":"Alessandro","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0291727","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]}}}